VKTX gets UBS target
VKTX is rallying violently with moderate volatility as a UBS price target and SUNRISE trial news for VK2735 draw buyers, while volume stays around normal.
Sources: https://www.boerse-express.com/news/articles/viking-therapeutics-aktie-startet-sunrise-fuer, https://www.ad-hoc-news.de/boerse/news/nebenwerte/ubs-sets-usd-94-target-for-viking-therapeutics-stock
Previous verdicts for VKTX
- AI Search: Viking Therapeutics Slips Modestly Amid Profit Taking — 2026-10-23
- AI Search: VKTX Slips as Macro Sell-Off Overshadows Positive Pipeline News — 2026-10-16
- AI Search: Viking Therapeutics Slips Slightly as Oral Obesity Drug Enters Phase 3 — 2026-10-14
- AI Search: Viking Therapeutics Slips Below Key Moving Average as Truist Trims Target — 2026-10-13
- AI Search: Viking Therapeutics Rides Oral Obesity Pill Narrative Higher — 2026-10-09
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works